Cerafix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cerafix

Quick Facts

Property Description
Active Ingredient Cefixime
Form Tablet, Capsule, Oral Suspension
Pharmacological Class Third-Generation Cephalosporin Antibiotic
Common Use Treating bacterial infections
Origin Synthetic Compound

What Type of Medicine is Cefixime?

Cerafix is the brand name for a prescription-only medicine whose active ingredient is Cefixime, which is classified as a third-generation cephalosporin antibiotic. This medication's primary function is to serve as a bactericidal agent in the management of susceptible bacterial infections.

Cefixime is recognized as an essential medicine, underscoring its therapeutic importance in global health. Being a third-generation agent implies that it possesses a broad spectrum of activity, a characteristic clinically recognized for providing efficacy against a wide range of common bacterial pathogens, positioning it as an important tool in infectious disease treatment.

The Composition and Origin of Cerafix

The core of Cerafix is the active ingredient Cefixime, a synthetic compound manufactured as a single active ingredient product. The medicine is formulated for oral administration, typically available as a tablet, capsule, or a liquid oral suspension.

The drug is not derived from natural sources but is wholly synthesized in a laboratory setting, ensuring consistency and purity of the chemical substance. The provision of both solid and suspension dosage forms is critical for patient compliance. For example, the oral suspension preparation serves a key differentiating purpose by making the drug accessible to pediatric patients who cannot swallow tablets. This oral preparation is designed to be effectively absorbed through the digestive system to allow the antibiotic to reach the sites of infection within the body.

How Cefixime Fights Bacterial Infections

Cefixime is a powerful bactericidal agent because its core mechanism involves the inhibition of bacterial cell wall synthesis, leading to the direct killing of the harmful pathogens.

The medication works by targeting the specific proteins that bacteria rely on to build and maintain their rigid protective outer wall. By disabling this construction process, Cefixime compromises the structural integrity of the bacterial cell, causing it to rupture and die. This action defines its role in providing effective resolution of the underlying bacterial infection by actively eliminating the source of the disease.

Regulatory References

  1. Cefixime: MedlinePlus Drug Information

What side effects are possible with Cerafix?

Possible Side Effects and Safety Information

The official safety profile for Cerafix (Cefixime) classifies potential adverse reactions primarily based on the physiological system affected and their reported incidence rate. The most frequently documented effects relate to the Gastrointestinal System.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to their occurrence in clinical data and post-marketing reports:

  • Common: The most frequently reported effect is diarrhea.
  • Uncommon: Effects often listed in this category include headache, nausea, vomiting, and abdominal pain.
  • Rare / Very Rare: These categories cover infrequent events such as specific hematological changes (e.g., leukopenia) and certain severe skin or hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

The regulatory profile explicitly highlights the risk of several serious adverse reactions. These include potentially life-threatening anaphylactic/anaphylactoid reactions and severe skin conditions, such as Stevens-Johnson Syndrome (SJS). The medication may also be associated with Clostridium difficile-Associated Diarrhea (CDAD), which can range in severity and may occur during or up to two months after treatment cessation.

Cefixime is strictly contraindicated in patients with a known allergy to the cephalosporin class of antibiotics. Due to the relationship between these drug classes, caution is also required for patients with a history of penicillin hypersensitivity.

Population-Specific Safety Notes

The official labeling includes specific considerations for certain patient groups. For individuals with renal impairment, dose adjustments are required to mitigate the increased risk of neurological adverse events, such as seizures. Safety and efficacy have not been established in pediatric patients under 6 months of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cerafix (Cefixime) overdose is defined by the potential for severe neurological manifestations and the required immediate emergency response, with no specific antidote known.

Overdose Scope Official Regulatory Statements
Documented Overdose Presentations Excessive exposure may result in encephalopathy, with documented symptoms including seizures (convulsions), confusion, impaired consciousness, and abnormal movements.
Population-Specific Overdose Notes The risk of seizures is specifically heightened in patients with renal impairment where drug clearance is compromised. Regulatory data confirms hemodialysis and peritoneal dialysis do not remove significant quantities of Cefixime.
Emergency-Response Statements There is no specific antidote for Cefixime overdosage. Management requires symptomatic and supportive treatment, with anticonvulsant therapy administered if seizures occur.

When Immediate Medical Help is Required

  • Call emergency services (e.g., 911) or a Poison control helpline (e.g., 1-800-222-1222) immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • The drug must be discontinued if seizures are associated with the therapy.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by the risk of severe neurological symptoms, particularly seizures, which is compounded by existing renal impairment. Since no specific antidote is known and dialysis is ineffective for clearance, regulatory guidance mandates immediate contact with emergency services for severe manifestations to ensure prompt supportive treatment.

Therapeutic Uses of Cerafix

What Cerafix Treats: Main Uses and Benefits

Cerafix (Cefixime) may be applied across domains where additional symptomatic support is needed, typically in conditions characterized by periods of heightened symptoms caused by susceptible bacteria. Its therapeutic support aims at addressing the infectious cause, which supports the easing of the overall symptom load associated with the infection.

The medication is commonly used across conditions presenting with acute episodes, including upper respiratory infections like otitis media, pharyngitis, and tonsillitis; urinary conditions such as uncomplicated UTIs; lower airway issues related to periods of heightened symptoms in chronic bronchitis; specific systemic infections like certain enteric fever presentations; and certain sexually transmitted infections.

In these clinical settings, the medication helps address symptom clusters related to localized inflammation and physical discomfort. The use of Cefixime may offer supportive relief that contributes to improved comfort during symptomatic periods, particularly when symptoms interfere with routine activities.

Quick Fact: Support for Acute Discomfort
Common Context Conditions involving acute inflammation (e.g., ear pain, sore throat, painful urination).
Usage Context Applied in scenarios requiring temporary assistance in managing infection-related distress.
Patient Benefit Supports the patient during difficult episodes by easing the symptom burden.

Regulatory References

  1. NIH MedlinePlus overview of Cefixime

Eligibility and Restrictions for Use

Who can and cannot use Cerafix?

The eligibility profile for Cerafix (Cefixime) is strictly defined by government regulatory documents based on patient status, organ function, and allergy history.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with known allergy or hypersensitivity to Cefixime or any other cephalosporin antibiotic
Age-related eligibility rules Approved for adults and pediatric patients six months of age and older. Safety is not established in infants younger than six months.
Condition-specific eligibility rules Patients with impaired renal function require special consideration; use is conditional on appropriate dose assessment. Caution is advised for those with a history of penicillin allergy.
Pregnancy and lactation eligibility status Pregnancy: Use only if clearly needed. Lactation: Temporary discontinuation of nursing should be considered.

Eligibility Classifications (High-Level)

Category Official Regulatory Statement
Eligibility severity classification Contraindicated (Absolute Prohibition), Not Recommended (Infants, certain metabolic disorders), Use with Caution (Renal Impairment, Penicillin Allergy)
Eligibility-context constraints Defined by Hypersensitivity Status, Age Threshold, and Renal Function Status.

Resulting Eligibility Structure

Official eligibility statements:

  • Cerafix is contraindicated for patients with a known hypersensitivity to the cephalosporin class of antibiotics or the active ingredient.
  • Use is approved for adults and pediatric patients six months of age and older.
  • The safety and efficacy have not been established in infants less than six months old.

Connection to the overall eligibility profile

Regulatory documents establish that Cerafix is only eligible for use in individuals who meet specific age thresholds and who possess normal class tolerance. Eligibility is further restricted for patients with significantly impaired renal function, while hepatic insufficiency generally does not require modification.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information

Category Official Regulatory Statement
Medicinal product categories with documented interactions Anticoagulants (coumarin-type), Uricosurics.
Specific interacting medicines Warfarin, Carbamazepine, Probenecid.
Mechanistic basis of interactions Pharmacodynamic (PD) Interaction: Additive risk of coagulation effects. Transporter-Mediated/Renal Clearance: Reduced clearance of Cefixime. Pharmacokinetic (PK) Interaction: Alteration of co-administered drug levels.

Official Interaction Statements

  • Co-administration with Warfarin and coumarin-type anticoagulants has been reported to cause an increase in prothrombin time (PT), which may manifest with or without clinical bleeding. This additive risk to coagulation status is noted in patients with renal impairment.
  • Cefixime has been reported in postmarketing experience to cause a significant elevation in the plasma levels of Carbamazepine when taken concomitantly.
  • Co-administration with Probenecid is documented to reduce the total clearance of Cefixime due to inhibition of renal excretion.
  • Cefixime may produce false-positive results in urine glucose tests that rely on copper reduction methods (e.g., Benedict's or Fehling's solution) and may cause a false-positive direct Coombs test.

Connection to the Overall Interaction Profile

Regulatory documents define the product’s interaction structure primarily through two specific patterns: an additive risk of coagulation parameter prolongation when combined with anticoagulants, and the documented increase in exposure of the co-administered drug Carbamazepine. A transporter-mediated interaction is established with Probenecid, resulting in reduced Cefixime clearance. The remaining constraints relate to the potential for interference with specific laboratory diagnostic tests.

Mechanism of Action

Cefixime's mechanism involves disrupting the structure and survival of susceptible bacteria at a molecular level. The mechanism operates through two primary domains based on targeting structures unique to the bacterial cell.

Molecular Targeting of Bacterial Cell Wall Assembly

This domain describes how the active ingredient, Cefixime, directly and irreversibly targets Penicillin-Binding Proteins (PBPs), which are bacterial enzymes responsible for building the structural layer of the cell wall. By forming a stable, covalent bond with the PBP's active site, Cefixime permanently inhibits the transpeptidase activity necessary for peptidoglycan cross-linking.

Initiating Bactericidal Cellular Lysis

The cessation of cell wall synthesis leads to a critical structural defect, making the bacteria vulnerable to their own internal osmotic pressure. This physiological consequence results in the rupture (lysis) of the pathogen's cell membrane. This destructive cascade leads to a bactericidal action, resulting in the active killing and elimination of the susceptible microbial population.

Dosage and Administration Information

How to Use Cerafix: Official Administration Guidelines

Cerafix, the brand name for Cefixime, is an oral medication. The official instructions for its use detail specific forms, dosing regimens, and required procedural steps to ensure standardized administration.


Official Administration and Dosing

Feature Guideline (Strictly Label-Based)
Route of administration Oral (via tablet, capsule, or liquid suspension)
Standard Adult Dose 400 mg total daily dose
Frequency Administered either as 400 mg once daily or as 200 mg every 12 hours
Timing in relation to meals Tablets and capsules may be taken without regard to food
Course Duration Typically 7 to 14 days, though 10 full days is the minimum for certain infections

Administration Requirements and Adjustments

Administration depends heavily on the prescribed dosage form. The oral suspension must be reconstituted and shaken well before each use. Similarly, the chewable tablet form must be completely chewed or crushed before swallowing, as required by the prescribing information.

Official guidelines specify dose adjustments for patients with renal impairment. For example, patients with moderate to severe kidney function decline (CrCl 59 mL/min) require a reduced dose, such as 200 mg or 300 mg daily, as defined in the official regimen.

For pediatric patients over 6 months, the dose is calculated based on body weight (8 mg/kg/day), administered as a single daily dose or a divided dose. The final procedural structure requires a complete course of therapy to be administered, and patients are instructed not to double the dose to compensate for any missed timing.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cerafix (Cefixime)

The research evidence for Cerafix is based on several types of studies, including Randomized Controlled Trials (RCTs), comparative studies, and observational reports. This overview details what those studies examined, how findings were described, and what aspects of the medicine's use remain a subject of ongoing research, according to scientific and regulatory sources.


Evidence for Uncomplicated Urinary Tract Infections (UTIs)

Research was studied for conditions characterized by acute or disruptive episodes, such as uncomplicated UTIs. These studies monitored two main outcomes: the clearance of bacteria from the urine (bacteriological eradication) and the resolution of physical discomfort and other symptoms related to the infection.

Trials reported measured outcomes related to pathogen clearance in the urine at the test-of-cure visit, noting the susceptibility of the causative bacteria at the time of the study. However, the scientific literature highlights that evidence is limited regarding the long-term patterns of UTIs, as follow-up durations were limited.


Evidence for Acute Otitis Media (AOM) and Pharyngitis/Tonsillitis

Research examined the use of Cefixime for upper respiratory infections, including AOM (ear infections) and pharyngitis/tonsillitis (sore throat). The research primarily consisted of comparative clinical trials involving both adults and pediatric patients (children older than 6 months). Studies monitored outcomes related to physical discomfort and the specific clearance of known causative pathogens.

For AOM, research explored outcomes by comparing Cefixime against other established antibiotic agents. For pharyngitis, studies examined short-course Cefixime regimens by comparing them to the standard 10-day penicillin regimen for microbiological clearance. Data for certain groups remain insufficient, particularly concerning the long-term recurrence rates.


Research in Special Populations and Areas of Uncertainty

Pediatric patients (children) were included in studies for conditions like AOM and pharyngitis. For older adults and individuals with certain comorbid conditions, data show patterns related to use primarily in observational and post-marketing settings, but subgroup findings are uncertain due to limited targeted comparative studies.

A major area of research uncertainty relates to antimicrobial resistance. Study findings were observed to be associated with the local resistance patterns of the pathogen being studied. Research highlights what is known — and what is still uncertain. The results apply only to the populations studied and the specific conditions under which they were conducted.

Key Studies & References

  1. Clinical pharmacokinetics of cefixime: a systematic review (Supporting PK/Duration/Dosing relevance to efficacy)

Frequently Asked Questions (FAQ)

Common questions about Cerafix (FAQ)


Q: Can Cerafix be taken long-term?

Regulatory information emphasizes that the full prescribed course should be administered to address the infection and minimize the potential for developing antibiotic resistance. Cerafix is intended for short-term use, typically for a prescribed duration of 7 to 14 days. Longer-term or repeated use is not generally covered in initial guidance and may require special monitoring.


Q: Is it common to feel tired when starting Cerafix?

Official labeling indicates that general fatigue or unusual tiredness is not listed among the most common side effects. However, both unusual tiredness and drowsiness are documented as less common or rare adverse reactions. These effects are sometimes noted in connection with more significant underlying health issues.


Q: What are the most common side effects of Cerafix that people report?

Regulatory documents describe the most frequently reported adverse effects as related to the digestive system. The most common of these include diarrhea and loose stools. Other effects reported frequently, though considered uncommon, include nausea, abdominal pain, and general stomach discomfort.


Q: Does Cerafix interact with alcohol?

Official regulatory documents for Cefixime do not identify a specific major drug interaction with alcohol. However, general patient safety documentation often recommends caution regarding the concurrent use of alcohol with medications.


Q: Is Cerafix known to interact with common pain relievers like ibuprofen?

Official product labeling does not list a direct interaction between Cefixime and ibuprofen. Cefixime is documented to interact with certain blood thinners (anticoagulants), and regulatory documents describe risks when combining Cefixime with blood thinners, and general safety statements suggest that combining drugs with similar risks requires careful consideration.


Q: Is Cerafix safe for people over 65?

Cefixime is used by older adults. However, regulatory guidance indicates that dose adjustments are required for individuals with moderate or severe kidney function decline. Official documentation indicates that careful monitoring and consideration of revised dosing may be necessary for these individuals.


Q: Can Cerafix be used by people with high blood pressure?

According to official regulatory warnings, high blood pressure (hypertension) is not listed as a contraindication for Cefixime use. Official constraints on eligibility focus primarily on known allergies, severe diarrhea (colitis), and impaired kidney function.


Q: How does the way Cerafix works compare to older treatments for the same condition?

Official classification identifies Cefixime as a third-generation cephalosporin antibiotic. It is a bactericidal agent, meaning it actively kills bacteria by disrupting the synthesis of the bacterial cell wall. The 'third-generation' classification generally indicates a broader range of action against certain common bacteria compared to some older antibiotic classes like first-generation cephalosporins or standard penicillins.


Q: What if Cerafix does not seem to be working after a few weeks?

Official guidance notes the importance of administering the full prescribed course of Cerafix, even if symptoms begin to clear quickly. If the infection persists or seems to worsen after the prescribed treatment duration is completed, this may signal the growth of resistant bacteria.


Q: Does Cerafix cause skin rashes?

Official product information lists skin rashes and hives among the documented potential hypersensitivity reactions. Cefixime has also been rarely associated with severe and life-threatening skin reactions, such as Stevens-Johnson Syndrome (SJS).


Q: Does Cerafix make people feel anxious?

Regulatory labeling for Cefixime does report anxiety as a possible adverse effect. This is listed in the profile of non-common side effects related to the central nervous system.


Q: Can Cerafix make you feel jittery or restless?

While the terms 'jittery' or 'restless' are not used in official documents, regulatory information does include agitation and irritability among the less common adverse effects. These effects are generally associated with the central nervous system.


Q: How quickly does Cerafix usually start working?

According to pharmacokinetics data, Cefixime reaches its peak concentration in the bloodstream approximately 2 to 6 hours after a dose. Generally, patients who respond to the drug often report beginning to feel better within the first few days of starting the prescribed regimen.


Q: If I miss a dose of Cerafix, what generally happens?

Official regulatory documents describe a procedure where a missed dose is taken as soon as it is remembered. If the time for the next scheduled dose is approaching, the documentation states that the missed dose is skipped. It is specifically stated that the dose should not be doubled to make up for the one that was missed.


Q: What happens if you stop taking Cerafix suddenly?

Official product information emphasizes that the full prescribed duration of Cefixime should be administered, even if symptoms improve quickly. Discontinuing the medication early may result in the infection returning and potentially allowing the remaining bacteria to develop resistance to the antibiotic.


Q: How does Cerafix affect sleep patterns?

Official regulatory documents do not list sleep patterns as a documented side effect of Cefixime. However, drowsiness is listed among the less common side effects related to the central nervous system.


Q: Is it okay to take Cerafix with vitamins or supplements?

The official regulatory information primarily focuses on interactions with other prescription medications like warfarin and carbamazepine. Specific interactions with most common vitamins or supplements are not listed in the product labeling.


Q: Does Cerafix cause weight gain?

General weight gain is not listed as a common side effect in the regulatory profile for Cefixime. Official documentation reports rapid weight gain or unusual weight loss as rare symptoms that may be associated with more serious underlying adverse events, such as those affecting the kidney or blood.


Q: What is the difference between Cerafix and [Similar Drug Name]?

Cefixime is classified by regulatory bodies as an orally-active third-generation cephalosporin antibiotic. Third-generation agents are distinguished by their chemical structure, which provides a broad spectrum of activity against a wide range of common bacterial pathogens.


Q: If Cerafix works, how long does the effect usually last after taking a dose?

Pharmacokinetic data from official sources indicate that Cefixime has a serum half-life that averages approximately 3 to 4 hours in healthy individuals. This duration of activity supports the recommended dosing regimens of once or twice daily.


Q: What does the FDA label say about taking Cerafix with grapefruit juice?

Official regulatory documents, including FDA labeling, do not list a specific interaction or contraindication regarding the consumption of grapefruit juice with Cefixime. The medication is generally labeled to be taken with or without food.


Q: How do regulatory agencies classify the safety profile of Cerafix?

Regulatory verification classifies Cefixime as a prescription-only medicine. Furthermore, the World Health Organization includes Cefixime on its Model List of Essential Medicines, which recognizes it as an important agent for managing certain infectious diseases globally.


Q: Do people typically have to take Cerafix at a specific time of day?

Official administration instructions generally describe Cefixime as being taken at around the same times every day. This consistent timing helps maintain steady levels of the medication in the body, although the official guidance notes the medication can be taken without regard to food.


Q: What is the risk of a serious allergic reaction to Cerafix?

Official product safety information documents that serious allergic reactions, such as anaphylaxis and severe skin conditions, are rare risks associated with Cefixime. These severe events are stated to occur in a small number of people, and regulatory warnings state that immediate medical attention is required if signs of a serious reaction develop.

How should Cerafix be stored and disposed of?

How to Store and Dispose of Cerafix

Cerafix (Cefixime) must be stored strictly according to the regulatory label to maintain its stability. Tablets and unreconstituted powder require storage at Controlled Room Temperature (20 C to 25 C). The medication must be kept in its tightly closed original container, protected from excess heat, moisture, and light, and kept from freezing.

Stability and Child Safety

The prepared oral suspension is stable for 14 days and must be discarded afterward, even if refrigerated. All forms of Cerafix must be stored out of the reach of children.

Disposal

Outdated or unused medicine should be disposed of by following instructions from a pharmacist or using a community drug take-back program. Cefixime is generally not recommended to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cerafix found in:

A-Z Index: